loading
Precedente Chiudi:
$3.07
Aprire:
$3.05
Volume 24 ore:
9.64M
Relative Volume:
1.03
Capitalizzazione di mercato:
$1.12B
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.8323
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
+0.00%
1M Prestazione:
-18.18%
6M Prestazione:
-69.91%
1 anno Prestazione:
-74.07%
Intervallo 1D:
Value
$2.89
$3.09
Intervallo di 1 settimana:
Value
$2.89
$3.47
Portata 52W:
Value
$2.70
$14.23

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Nome
Iovance Biotherapeutics Inc
Name
Telefono
(650) 260-7120
Name
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Dipendente
838
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
3.06 1.12B 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-24 Iniziato UBS Buy
2024-07-29 Downgrade Piper Sandler Overweight → Neutral
2023-11-20 Iniziato Goldman Buy
2023-09-18 Reiterato Barclays Overweight
2023-05-30 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-27 Aggiornamento Piper Sandler Neutral → Overweight
2022-12-09 Downgrade Goldman Buy → Neutral
2022-10-31 Iniziato Guggenheim Neutral
2022-08-18 Ripresa Wells Fargo Equal Weight
2022-01-28 Aggiornamento Stifel Hold → Buy
2021-12-07 Ripresa Cowen Outperform
2021-06-10 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 Downgrade Piper Sandler Overweight → Neutral
2021-05-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 Downgrade Stifel Buy → Hold
2021-05-03 Iniziato Truist Buy
2021-04-16 Iniziato Goldman Buy
2021-03-08 Aggiornamento H.C. Wainwright Neutral → Buy
2020-12-15 Downgrade H.C. Wainwright Buy → Neutral
2020-10-06 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-22 Iniziato Mizuho Buy
2020-03-04 Iniziato Barclays Overweight
2020-02-26 Reiterato H.C. Wainwright Buy
2020-02-26 Reiterato Oppenheimer Outperform
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-10-01 Iniziato Stifel Buy
2019-04-29 Iniziato Piper Jaffray Overweight
2019-02-28 Reiterato Chardan Capital Markets Buy
2019-02-07 Iniziato Robert W. Baird Outperform
2018-12-31 Ripresa B. Riley FBR Buy
2018-07-06 Reiterato Chardan Capital Markets Buy
2018-04-10 Aggiornamento B. Riley FBR, Inc. Neutral → Buy
2018-03-13 Reiterato B. Riley FBR, Inc. Neutral
2018-02-23 Downgrade B. Riley FBR, Inc. Buy → Neutral
2018-01-25 Reiterato H.C. Wainwright Buy
2017-11-01 Reiterato B. Riley FBR, Inc. Buy
Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

pulisher
Apr 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts? - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Apr 18, 2025
pulisher
Apr 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 17, 2025

11 Most Promising Penny Stocks According to Analysts - Insider Monkey

Apr 17, 2025
pulisher
Apr 16, 2025

Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey

Apr 15, 2025
pulisher
Apr 14, 2025

Barclays Adjusts Iovance Biotherapeutics (IOVA) Price Target Ami - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Is Iovance Biotherapeutics a Millionaire-Maker? - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Barclays cuts Iovance Biotherapeutics target to $5, keeps rating By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 13, 2025

Iovance Biotherapeutics (IOVA) Eyes Revenue Growth with TIL Ther - GuruFocus

Apr 13, 2025
pulisher
Apr 10, 2025

TILs’ Tomorrow Bringing More Cancers Under Immune Control - Genetic Engineering and Biotechnology News

Apr 10, 2025
pulisher
Apr 09, 2025

Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025
pulisher
Apr 08, 2025

10 Stocks Under $10 that Will Triple - Insider Monkey

Apr 08, 2025
pulisher
Apr 07, 2025

Trading (IOVA) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 04, 2025

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction - Yahoo Finance

Apr 04, 2025
pulisher
Apr 03, 2025

Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail

Apr 03, 2025
pulisher
Apr 03, 2025

Iovance: Less And Less Likely To Reap Reward From Its Pioneering Work (NASDAQ:IOVA) - Seeking Alpha

Apr 03, 2025
pulisher
Apr 01, 2025

Institutional Investors May Adopt Severe Steps After Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Latest 8.3% Drop Adds to a Year Losses - 富途牛牛

Apr 01, 2025
pulisher
Apr 01, 2025

Tumor-Infiltrating Lymphocytes Treatment Market Size in 7MM - openPR.com

Apr 01, 2025
pulisher
Apr 01, 2025

Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com

Apr 01, 2025
pulisher
Mar 27, 2025

Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey

Mar 25, 2025
pulisher
Mar 22, 2025

1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - AOL.com

Mar 22, 2025
pulisher
Mar 21, 2025

Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly

Mar 18, 2025
pulisher
Mar 17, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 15, 2025

10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey

Mar 15, 2025
pulisher
Mar 13, 2025

Iovance at Barclays Conference: Strategic Growth and Expansion - Investing.com

Mar 13, 2025
pulisher
Mar 12, 2025

Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL

Mar 10, 2025
pulisher
Mar 09, 2025

Can Amtagvi Drive IOVA's Return To Glory - RTTNews

Mar 09, 2025
pulisher
Mar 07, 2025

IOVA stock touches 52-week low at $3.62 amid market challenges - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World

Mar 04, 2025

Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Iovance Biotherapeutics Inc Azioni (IOVA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Bellemin Jean-Marc
Chief Financial Officer
Mar 03 '25
Option Exercise
0.00
58,590
0
87,938
BILINSKY IGOR
Chief Operating Officer
Mar 03 '25
Option Exercise
0.00
62,106
0
120,880
Vogt Frederick G
Interim CEO & General Counsel
Mar 03 '25
Option Exercise
0.00
223,943
0
445,059
Puri Raj K.
Chief Regulatory Officer
Mar 03 '25
Option Exercise
0.00
59,999
0
215,411
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Mar 03 '25
Option Exercise
0.00
62,497
0
126,383
Vogt Frederick G
Interim CEO & General Counsel
Jan 14 '25
Option Exercise
0.00
20,835
0
231,071
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jan 14 '25
Option Exercise
0.00
2,813
0
65,464
BILINSKY IGOR
Chief Operating Officer
Jan 14 '25
Option Exercise
0.00
2,813
0
60,352
Puri Raj K.
Chief Regulatory Officer
Dec 16 '24
Option Exercise
0.00
8,334
0
159,171
Vogt Frederick G
Interim CEO & General Counsel
Dec 02 '24
Option Exercise
0.00
10,417
0
214,662
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
Capitalizzazione:     |  Volume (24 ore):